Vedolizumab Biosimilar (Intas Pharmaceuticals)

N/A

Report date: 2025/05/07 15:05:21

Base Information

Drug NameVedolizumab Biosimilar (Intas Pharmaceuticals)
Drug Alias NameINTP53INTP-53
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionIntegrin alpha-4/beta-7 antagonistsMucosal addressin cell adhesion molecule-1 inhibitors
TargetsIntegrin alpha-4/beta-7Mucosal addressin cell adhesion molecule-1
Therapy Area/IndicationsColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesIntas Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIntas Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsColitis, Ulcerative
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A